225 related articles for article (PubMed ID: 34801015)
1. The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics.
Gittoes N; Rejnmark L; Ing SW; Brandi ML; Björnsdottir S; Hahner S; Hofbauer LC; Houillier P; Khan AA; Levine MA; Mannstadt M; Shoback DM; Vokes TJ; Zhang P; Marelli C; Germak J; Clarke BL
BMC Endocr Disord; 2021 Nov; 21(1):232. PubMed ID: 34801015
[TBL] [Abstract][Full Text] [Related]
2. Five-Year Estimated Glomerular Filtration Rate in Adults with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study.
Ayodele O; Rejnmark L; Mu F; Lax A; Berman R; Swallow E; Gosmanova EO
Adv Ther; 2022 Nov; 39(11):5013-5024. PubMed ID: 36018496
[TBL] [Abstract][Full Text] [Related]
3. Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study.
Clarke BL; Vokes TJ; Bilezikian JP; Shoback DM; Lagast H; Mannstadt M
Endocrine; 2017 Jan; 55(1):273-282. PubMed ID: 27734257
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
[TBL] [Abstract][Full Text] [Related]
5. Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84).
Chen KS; Gosmanova EO; Curhan GC; Ketteler M; Rubin M; Swallow E; Zhao J; Wang J; Sherry N; Krasner A; Bilezikian JP
J Clin Endocrinol Metab; 2020 Oct; 105(10):e3557-65. PubMed ID: 32738041
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism.
Vokes TJ; Mannstadt M; Levine MA; Clarke BL; Lakatos P; Chen K; Piccolo R; Krasner A; Shoback DM; Bilezikian JP
J Clin Endocrinol Metab; 2018 Feb; 103(2):722-731. PubMed ID: 29099947
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.
Mannstadt M; Clarke BL; Vokes T; Brandi ML; Ranganath L; Fraser WD; Lakatos P; Bajnok L; Garceau R; Mosekilde L; Lagast H; Shoback D; Bilezikian JP
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):275-83. PubMed ID: 24622413
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism.
Mannstadt M; Clarke BL; Bilezikian JP; Bone H; Denham D; Levine MA; Peacock M; Rothman J; Shoback DM; Warren ML; Watts NB; Lee HM; Sherry N; Vokes TJ
J Clin Endocrinol Metab; 2019 Nov; 104(11):5136-5147. PubMed ID: 31369089
[TBL] [Abstract][Full Text] [Related]
9. Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety.
Tay YD; Tabacco G; Cusano NE; Williams J; Omeragic B; Majeed R; Gomez Almonte M; Bilezikian JP; Rubin MR
J Clin Endocrinol Metab; 2019 Nov; 104(11):5601-5610. PubMed ID: 31310310
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human parathyroid hormone (1-84) replacement therapy in a child with hypoparathyroidism.
Laurer E; Grünberger J; Naidoo U; Lanzersdorfer R; Wimleitner M; Tischlinger K; Högler W
Bone; 2021 Mar; 144():115834. PubMed ID: 33359892
[TBL] [Abstract][Full Text] [Related]
11. Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study.
Ayodele O; Mu F; Berman R; Swallow E; Rejnmark L; Gosmanova EO; Kaul S
Adv Ther; 2022 Aug; 39(8):3845-3856. PubMed ID: 35696069
[TBL] [Abstract][Full Text] [Related]
12. Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism.
Marcucci G; Della Pepa G; Brandi ML
Expert Opin Drug Saf; 2017 May; 16(5):617-625. PubMed ID: 28332412
[TBL] [Abstract][Full Text] [Related]
13. AN OPEN-LABEL EXTENSION STUDY OF PARATHYROID HORMONE RHPTH(1-84) IN ADULTS WITH HYPOPARATHYROIDISM.
Lakatos P; Bajnok L; Lagast H; Valkusz Z
Endocr Pract; 2016 May; 22(5):523-32. PubMed ID: 26684150
[TBL] [Abstract][Full Text] [Related]
14. Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy.
Tabacco G; Tay YD; Cusano NE; Williams J; Omeragic B; Majeed R; Almonte MG; Rubin MR; Bilezikian JP
J Clin Endocrinol Metab; 2019 Jul; 104(7):2748-2756. PubMed ID: 30776291
[TBL] [Abstract][Full Text] [Related]
15. Teriparatide (rhPTH 1-34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism.
Tuli G; Buganza R; Tessaris D; Einaudi S; Matarazzo P; de Sanctis L
Endocrine; 2020 Feb; 67(2):457-465. PubMed ID: 31705387
[TBL] [Abstract][Full Text] [Related]
16. Recombinant Human Parathyroid Hormone (1-84): A Review in Hypoparathyroidism.
Kim ES; Keating GM
Drugs; 2015 Jul; 75(11):1293-303. PubMed ID: 26177893
[TBL] [Abstract][Full Text] [Related]
17. Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety.
Rubin MR; Cusano NE; Fan WW; Delgado Y; Zhang C; Costa AG; Cremers S; Dworakowski E; Bilezikian JP
J Clin Endocrinol Metab; 2016 Jul; 101(7):2742-50. PubMed ID: 27144931
[TBL] [Abstract][Full Text] [Related]
18. Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial.
Rejnmark L; Gosmanova EO; Khan AA; Makita N; Imanishi Y; Takeuchi Y; Sprague S; Shoback DM; Kohlmeier L; Rubin MR; Palermo A; Schwarz P; Gagnon C; Tsourdi E; Zhao C; Makara MA; Ominsky MS; Lai B; Ukena J; Sibley CT; Shu AD
Adv Ther; 2024 Jun; 41(6):2500-2518. PubMed ID: 38691316
[TBL] [Abstract][Full Text] [Related]
19. Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1-84) treatment.
Marcucci G; Beccuti G; Carosi G; Cetani F; Cianferotti L; Colao AM; Di Somma C; Duradoni M; Elefante A; Ghizzoni L; Giusti M; Lania AG; Lavezzi E; Madeo B; Mantovani G; Marcocci C; Masi L; Parri S; Pigliaru F; Santonati A; Spada A; Vera L; Brandi ML
J Endocrinol Invest; 2022 Sep; 45(9):1653-1662. PubMed ID: 35460461
[TBL] [Abstract][Full Text] [Related]
20. The risk of chronic kidney disease development in adult patients with chronic hypoparathyroidism treated with rhPTH(1-84): A retrospective cohort study.
Rejnmark L; Ayodele O; Lax A; Mu F; Swallow E; Gosmanova EO
Clin Endocrinol (Oxf); 2023 Apr; 98(4):496-504. PubMed ID: 35974422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
